Towards Novel BIOmarkers to Diagnose SEPsis on the Emergency Room

What this Trial Is About

Researchers are studying patients who come to the Emergency Department with a suspected infection to understand the differences in immune response between those who develop sepsis and those who do not. The study also aims to identify immune response changes linked to a higher risk of sepsis and to examine the long-term cognitive and physical effects after sepsis hospitalization. Sepsis is defined here using the Sepsis 3.0 criteria, which considers organ failure measured by the SOFA score, reflecting dysfunction in six organ systems. The study does not involve any treatment interventions but observes patients who present with suspected infection and have a Modified Early Warning Score (MEWS) of 2 or higher. Researchers will use routine clinical measurements, including an adapted method for assessing respiratory function through the SpO2/FiO2 ratio, to determine organ failure. The study will follow patients during hospitalization and for up to four years afterward to monitor outcomes. Participants will be assessed with clinical observations and scoring systems to diagnose sepsis, evaluate disease severity during hospital stay, and track mortality over four years. Additional outcomes include length of hospital stay, readmissions up to five years, and post-sepsis complications up to one year after the sepsis episode. Data collection will include these medical outcomes without any study drug or intervention, focusing on observational follow-up and long-term health status.

Towards Novel BIOmarkers to Diagnose SEPsis on the Emergency Room